New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.
Frédéric Stauffer, Pascal Furet, Andreas Floersheimer, Marc Lang
Index: Bioorg. Med. Chem. Lett. 22(5) , 1860-3, (2012)
Full Text: HTML
Abstract
Aromatase inhibition is the new standard of care for estrogen receptor positive breast cancer and has also potential for treatment of other diseases such as endometriosis. Simple and readily available 3-pyridyl arylethers and 1-aryl pyrrolo[2,3-c]pyridines recapitulating the key pharmacophore elements of Letrozole (1) are described and their structure-activity relationships are discussed. Potent and ligand efficient leads such as compound 23 (IC(50)=59nM on aromatase) have been identified.Copyright © 2012 Elsevier Ltd. All rights reserved.
Related Compounds
Related Articles:
2005-03-24
[J. Med. Chem. 48(6) , 1745-58, (2005)]
Synthesis and characterization of all-conjugated graft copolymers comprised of n-type or p-type backbones and poly (3-hexylthiophene) side chains. Wang J, et al.
[Macromolecules 46(5) , 1783-1793, (2013)]